Commentary

JCP
Bipolar Disorder and PMDD: Comorbidity Conundrum
Commentary

October 26, 2022

Teri Pearlstein, MD, discusses a recent review that highlights the difficulties of diagnosing PMDD in women with bipolar disorder.
JCP
Relationship Between MDD and Medical Conditions
Commentary

October 19, 2022

This commentary by Rachel A. Weir, MD, and Mark Hyman Rapaport, MD, discusses the article by Alix M. Arnaud, MSc, and colleagues on the overlap between major depressive disorder...
,
JCP
Lost in Translation: The Value of Psychiatric Clinical Trials
Commentary

October 17, 2022

John C. Markowitz, MD, and Barbara L. Milrod, MD, assert the value of clinical trials in psychiatry and outline reasons why NIMH should resume supporting them.
,
JCP
Ketamine in the Real World: Where Do We Go From Here?
Commentary

September 14, 2022

Dr Wilkinson comments on recent data and developments in the use of ketamine for mood disorders.
JCP
Positive Predictive Value
Commentary

August 24, 2022

In this Commentary, the author posits that knowledge about positive predictive value—the probability a person identified as ill by a screening test does indeed have the illness—is important for...
JCP
Psychiatric Care Considerations for Sexually and Gender Diverse Populations
Commentary

July 18, 2022

Dr Keuroghlian discusses recent research by Oka et al on LGBTQ patients’ clinical characteristics and response to ECT.
JCP
Accumulation of Reproductive Safety Data for SGAs
Commentary

June 8, 2022

This commentary on an article by Yakuwa and colleagues calls for an acceleration of the acquisition of clinical data on the safety of second-generation antipsychotics for pregnant women and...
JCP
Should Blind Psychiatrists Be Paid Less?
Commentary

May 23, 2022

Dr Zimmerman comments on a recent meta-analysis by Scott and colleagues on the use of video-based telehealth in treatment of PTSD.
PCC
Gandhian Concepts on Mental Health in Contemporary COVID-19 Pandemic Times
Commentary

April 19, 2022

In this commentary, the authors discuss Gandhi’s views on mental health, especially in the context of the COVID-19 pandemic.
, , , et al
PCC
US Suicide Rates and Impact of Major Disasters
Commentary

April 12, 2022

This commentary explores the impact of major disasters on suicide rates, especially in the context of the COVID-19 pandemic.
, , , et al
JCP
What Is the Role of Digital Medicine for Adherence Monitoring in Patients With SMI?
Commentary

April 11, 2022

This commentary looks at the benefits and limitations of digital medicine systems and discusses a recent trial in schizophrenia patients by Cohen et al.
JCP
Functional Outcomes of an Antipsychotic in Schizophrenia: Generalizable or Specific Effect?
Commentary

March 1, 2022

This commentary takes a closer look at Correll and colleagues’ findings on functional outcomes with brexpiprazole.
PCC
Commentary

January 20, 2022

In this commentary, the authors discuss biological similarities of the opioid epidemic and the COVID-19 pandemic, as well as differences in response to the 2 public health crises.
, ,
PCC
Commentary

January 20, 2022

Patients with psychiatric disorders may be at greater risk of experiencing adverse outcomes from COVID-19. Read on to find out more.
, ,
JCP
Commentary

January 18, 2022

This commentary discusses the article by Zeifman and colleagues on the role classic psychedelic agents may have in reducing risk of suicide.
,
JCP
Commentary

January 4, 2022

This commentary discusses the review by Vaccarino and colleagues of cognitive effects associated with ketamine treatment for major depressive disorder.
PCC
Commentary

December 16, 2021

In this commentary, the authors discuss the new Omicron variant of COVID-19 as well as the potential mental health challenges that will likely unfold over the next year.
,
PCC
Commentary

November 18, 2021

There are signs that the COVID-19 pandemic may disproportionately impact suicide rates among Black and other vulnerable populations in the US. This commentary explores this possibility in the context...
, ,
JCP
Commentary

November 9, 2021

In this commentary on an article by Amani and colleagues, Dr O’Hara discusses the role—and possible limits—of peer support for women with perinatal depression.
JCP
Commentary

November 2, 2021

This commentary discusses therapeutic inertia--failure to (1) establish an optimal treatment dose to reach a desired outcome and (2) change treatment when a first treatment does not produce remission—in...
PCC
Commentary

October 7, 2021

The issues related to the COVID-19 pandemic pose a unique challenge for those with autism spectrum disorder and their caregivers as well. Read this commentary to find out more.
, ,
PCC
Commentary

September 23, 2021

In this commentary, the author discusses the mental health effects of the second wave of the COVID-19 tsunami in India.
JCP
Commentary

August 3, 2021

This commentary discusses the results of a recent JCP article on the National Pregnancy Registry for Atypical Antipsychotics.
,
JCP
Commentary

May 18, 2021

This commentary discusses the article by Dubreucq and colleagues that examined objective and subjective aspects of recovery among clinically stable outpatients with schizophrenia spectrum disorders.
,

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe